A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild‐Type, Advanced Triple‐Negative Breast Cancer

LESSONS LEARNED: Monotherapy with prexasertib demonstrated modest activity in BRCA wild‐type, recurrent triple‐negative breast cancer, highlighting the unmet need for combination treatment strategies. Neutropenia, anemia, and thrombocytopenia are common with the use of prexasertib but are manageable...

Full description

Saved in:
Bibliographic Details
Published in:Oncologist
Main Authors: Gatti‐Mays, Margaret E., Karzai, Fatima H., Soltani, Sanaz N., Zimmer, Alexandra, Green, Jeffrey E., Lee, Min‐Jung, Trepel, Jane B., Yuno, Akira, Lipkowitz, Stanley, Nair, Jayakumar, McCoy, Ann, Lee, Jung‐Min
Format: Artigo
Language:Inglês
Published: John Wiley & Sons, Inc. 2020
Subjects:
Clinical Trial Results
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7938394/
https://ncbi.nlm.nih.gov/pubmed/32510664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0491
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items